tirzepatide surpass-4 SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide 10mg Research Peptide |

And a do not bill Medicare part D, please notify once denied

Mounjaro, known generically as tirzepatide, is Eli Lillys FDA-approved dual agonist medication that targets both GIP and GLP-1 receptors

We've worked with specialists to ensure the assessment provides sufficient clinical context for the healthcare provider to make an informed prescribing decision

Every week, you check in with a provider in the Hers app, which is easy to use

Long-acting GLP-1 receptor agonists have gained prominence due to their convenient dosing schedules and comprehensive glycemic effects

These medications are FDA-approved for chronic weight management in adults with a BMI of 30 or greater (obesity) or a BMI of 27 or greater (overweight) with at least one weight-related health condition such as hypertension, type 2 diabetes, or high cholesterol